- Home
- FDMT vs RAPT Comparison
FDMT vs RAPT Comparison
Compare FDMT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- RAPT
- Stock Information
- Founded
- FDMT 2013
- RAPT 2015
- Country
- FDMT United States
- RAPT United States
- Employees
- FDMT N/A
- RAPT N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- RAPT Health Care
- Exchange
- FDMT Nasdaq
- RAPT Nasdaq
- Market Cap
- FDMT 192.2M
- RAPT 194.2M
- IPO Year
- FDMT 2020
- RAPT 2019
- Fundamental
- Price
- FDMT $6.61
- RAPT $12.73
- Analyst Decision
- FDMT Buy
- RAPT Buy
- Analyst Count
- FDMT 9
- RAPT 5
- Target Price
- FDMT $30.63
- RAPT $33.60
- AVG Volume (30 Days)
- FDMT 733.0K
- RAPT 110.9K
- Earning Date
- FDMT 08-11-2025
- RAPT 08-07-2025
- Dividend Yield
- FDMT N/A
- RAPT N/A
- EPS Growth
- FDMT N/A
- RAPT N/A
- EPS
- FDMT N/A
- RAPT N/A
- Revenue
- FDMT $33,000.00
- RAPT N/A
- Revenue This Year
- FDMT $9,921.62
- RAPT N/A
- Revenue Next Year
- FDMT N/A
- RAPT N/A
- P/E Ratio
- FDMT N/A
- RAPT N/A
- Revenue Growth
- FDMT N/A
- RAPT N/A
- 52 Week Low
- FDMT $2.24
- RAPT $5.67
- 52 Week High
- FDMT $17.41
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- FDMT 57.82
- RAPT 61.74
- Support Level
- FDMT $5.97
- RAPT $11.15
- Resistance Level
- FDMT $7.33
- RAPT $12.13
- Average True Range (ATR)
- FDMT 0.48
- RAPT 0.80
- MACD
- FDMT -0.11
- RAPT 0.09
- Stochastic Oscillator
- FDMT 39.51
- RAPT 100.00
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.